What is CYPH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.32B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CYPH?

P/E (TTM) is n/a and 52-week range is $0.39 to $4.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CYPH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CYPH?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-4.06B, EPS (TTM) near $-0.10 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cypherpunk Technologies Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 106.5M shares outstanding, ISIN US52187K2006 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cypherpunk Technologies Inc

$CYPH

Health Care · Biotechnology

IR Run Scenarios

$2.94

+4.63%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Employees

Website

www.leaptx.com/

IPO

2017-01-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)